Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
1.
Ther Adv Respir Dis ; 14: 1753466620935772, 2020.
Article in English | MEDLINE | ID: mdl-32600177

ABSTRACT

BACKGROUND: The predominance of neutrophils in pleural effusions of patients with different serious impairments of the pleural cavity organs is often found. The aim of this study was to identify the type of injury using the cytological-energy analysis of pleural effusions. METHODS: We analysed 635 samples of pleural effusions with predominance of neutrophils. We compared the values of the coefficient of energy balance (KEB), lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) catalytic activities in the following subgroups of patients: with transudative effusions, purulent pneumonia, chest empyema and after chest surgery with and without purulent complications. Statistical analysis was performed using the ANOVA Kruskal-Wallis test (p < 0.05 was considered as significant). RESULTS: We found the lowest KEB values in pleural effusions of patients with chest empyema and their gradual increases in patients with purulent pneumonia and with transudative effusions. We observed the highest LDH and AST enzymes activity in patients with chest empyema and their gradual decrease in patients with purulent pneumonia and with transudative effusions. LDH and AST enzymes activity was significantly higher in pleural effusions of patients after chest surgery with purulent complications compared with non-purulent cases. CONCLUSION: The most intensive inflammation and the most extensive tissue destruction in the pleural cavity were found in patients with chest empyema. Significantly better parameters were observed in patients with purulent pneumonia. The absence of serious inflammation and the absence of tissue destruction were typical for patients with transudative effusions. Finally, our results confirmed an anticipated higher tissue destruction in patients after chest surgery. Significantly worse injury was found in surgical patients with purulent complications compared with non-purulent ones. The reviews of this paper are available via the supplemental material section.


Subject(s)
Empyema, Pleural/metabolism , Energy Metabolism , Neutrophils/metabolism , Pleural Effusion/metabolism , Pneumonia/metabolism , Postoperative Complications/metabolism , Aspartate Aminotransferases/analysis , Biomarkers/analysis , Empyema, Pleural/diagnosis , Empyema, Pleural/immunology , Humans , L-Lactate Dehydrogenase/analysis , Neutrophils/immunology , Pleural Effusion/diagnosis , Pleural Effusion/immunology , Pneumonia/diagnosis , Pneumonia/immunology , Postoperative Complications/diagnosis , Postoperative Complications/immunology , Retrospective Studies , Thoracic Surgical Procedures/adverse effects
2.
Cancer Lett ; 453: 184-192, 2019 07 01.
Article in English | MEDLINE | ID: mdl-30953706

ABSTRACT

Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas associated with chronic inflammation (DLBCL-CI) develop in patients with chronic inflammation but without any predisposing immunodeficiency. Given the expression of the EBV latent genes, DLBCL-CI should have mechanisms for evasion of host antitumor immunity. EBV-positive pyothorax-associated lymphoma (PAL) is a prototype of DLBCL-CI and may provide a valuable model for the study of immune evasion by DLBCL-CI. This study demonstrates that PAL cell lines express and secrete CCL17 and/or CCL22 chemokines, the ligands of C-C motif chemokine receptor 4 (CCR4), in contrast to EBV-negative DLBCL cell lines. Accordingly, culture supernatants of PAL cell lines efficiently attracted CCR4-positive regulatory T (Treg) cells in human peripheral blood mononuclear cells. PAL cells injected into mice also attracted CCR4-expressing Treg cells. Furthermore, this study confirmed that CCR4-expressing Treg cells were abundantly present in primary PAL tissues. Collectively, these findings provide new insight into the mechanisms of immune evasion by PAL, and further studies are warranted on whether such mechanisms eventually lead to the development of DLBCL-CI.


Subject(s)
Chemokine CCL17/biosynthesis , Chemokine CCL22/biosynthesis , Empyema, Pleural/immunology , Epstein-Barr Virus Infections/immunology , Lymphoma, Large B-Cell, Diffuse/immunology , T-Lymphocytes, Regulatory/immunology , Animals , Cell Line, Tumor , Chemokine CCL17/immunology , Chemokine CCL22/immunology , Empyema, Pleural/pathology , Empyema, Pleural/virology , Epstein-Barr Virus Infections/pathology , Humans , Inflammation/immunology , Inflammation/pathology , Inflammation/virology , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, Large B-Cell, Diffuse/virology , Male , Mice , Mice, Inbred BALB C , Receptors, CCR4/biosynthesis , Receptors, CCR4/immunology
3.
Chest ; 153(4): e71-e73, 2018 04.
Article in English | MEDLINE | ID: mdl-29626971

ABSTRACT

We retrospectively report four cases from two hospitals of nonpneumococcal pleural empyema with a likely false-positive result on the pneumococcal antigen test BinaxNOW (PATB) (Alere) performed in pleural fluid samples in patients with aspiration pneumonia risk factors. To determine whether the positive reaction was due to cross-reactivity, we separately tested the isolates from the pleural fluid samples, along with collection and reference strains. All patients had polymicrobial aerobic and anaerobic positive cultures, including Parvimonas micra in every case. In all cases, 16S rDNA polymerase chain reaction sequencing yielded Fusobacterium nucleatum. Samples for culture and specific polymerase chain reaction were negative for Streptococcus pneumoniae. We found that the false-positive PATB finding was likely due to P micra, a previously unknown cross-reactivity. In case of aspiration pneumonia risk factors, a positive PATB result must be interpreted with caution because there can be a false positivity due to anaerobic infection or co-infection.


Subject(s)
Empyema, Pleural/immunology , Adolescent , Adult , Antigens, Bacterial/metabolism , Child , Cross Reactions , False Positive Reactions , Female , Fusobacterium Infections/immunology , Fusobacterium nucleatum/immunology , Gram-Positive Bacterial Infections/immunology , Humans , Immunoassay/standards , Infant , Male , Pneumonia, Aspiration/immunology , Pneumonia, Pneumococcal/diagnosis , Streptococcus pneumoniae/immunology
4.
Pediatr Pulmonol ; 52(6): 757-762, 2017 06.
Article in English | MEDLINE | ID: mdl-28474458

ABSTRACT

BACKGROUND: Pleural empyema is a well-known complication of pneumonia. If treatment is delayed, empyema may increase morbidity and mortality in affected patients. Therefore, the identification of empyema biomarkers in parapneumonic pleural effusion is desirable. Previous research has suggested complement activation products as candidate empyema markers. OBJECTIVE: To compare the levels of complement activation products C3a, C5a, and C5b9 in pleural effusion induced by Staphylococcus aureus (SA), Streptococcus pneumoniae (SP), or turpentine (control). METHODS: Thirty-nine male Wistar rats (mean weight 414 g; 290-546 g) were allocated as follows: 17 animals in the SA group, 12 in the SP group, and 10 in the control group. Bacteria or turpentine were injected into the pleural space. After 12 hr, intrapleural fluid was collected using ultrasound-guided thoracentesis. Levels of complement activation products were determined using ELISA kits. RESULTS: Two SA and one SP animals died before 12 hr. Mean levels were as follows: C3a: 1066.82 µg/ml (937.29-1196.35 µg/ml) in SA, 1188.28 µg/ml (1095.65-1280.92 µg/ml) in SP, and 679.13 µg/ml (601.29-756.98 µg/ml) in controls (P < 0.001); C5a: 55.727 ng/ml (41.22-70.23 ng/ml) in SA, 520.107 ng/ml (278.92-761.3 ng/ml) in SP, and 5.268 ng/ml (1.68-8.85 ng/ml) in controls (P < 0.001); C5b9: 15.02 ng/ml (13.1-16.94 ng/ml) in SA, 16.63 ng/ml (14.37-18.9 ng/ml) in SP, and 14.05 ng/ml (9.8-18.29 ng/ml) in controls (P = 0.692). ROC analysis revealed an area under the curve of 0.987 (95% CI: 0.953-1) for C3a; 1 (1-1) for C5a; and 0.757 for C5b9 (0.523-0.990). CONCLUSIONS: In the present rat model, complement activation fragments C3a and C5a accurately detected infected pleural effusion. Pediatr Pulmonol. 2017;52:757-762. © 2017 Wiley Periodicals, Inc.


Subject(s)
Complement Activation , Empyema, Pleural/immunology , Pleural Effusion/immunology , Animals , Complement C3a/immunology , Complement C5a/immunology , Complement Membrane Attack Complex/immunology , Empyema, Pleural/etiology , Male , Pleural Effusion/etiology , Pneumococcal Infections/complications , Pneumococcal Infections/immunology , Rats, Wistar , Staphylococcal Infections/complications , Staphylococcal Infections/immunology , Staphylococcus aureus , Streptococcus pneumoniae
5.
Vojnosanit Pregl ; 73(3): 280-3, 2016 Mar.
Article in English | MEDLINE | ID: mdl-27295915

ABSTRACT

INTRODUCTION: Extraintestinal manifestations of nontyphoidal salmonellosis are usually seen in patients with cellular immunodeficiency. Pleural empyema caused by nontyphoidal Salmonella is very rare clinical presentation of salmonellosis and there are just a few cases described in a literature. We presented a very rare case of pleural empyema caused by Salmonella enteritidis in a patient with non-Hodgkin limphoma. CASE REPORT: A 60-year-old male with low grade B-cell lymphoma, mucosa associated lymphoid tissue (MALT) type in IV clinical degree, manifested with infiltration of stomach, bronchus, pleura and peritoneum was admitted to the hospital. Initially the patient was presented with non-specific symptoms and signs, suggesting poor general condition. During the hospitalization his pleural fluid became purulent and changes in blood counts were registered with the increase of leukocytes, especially neutrophils. A large number of leukocytes was found by microscopic evaluation of pleural fluid and Salmonella enteritidis was isolated by its culture. There were no pathogenic bacteria in stool culture and hemoculture remained sterile. Toxins A and B of Clostridium difficile were not detected in stool. The patient was treated by ciprofloxacin and cefrtiaxone for 14 days with drainage of the purulent content, what was followed by the resolution and organization of the pleural fluid. After the stabilization of his general condition, chemotherapy with cyclophosphamide, vincristine, prednisone (COP) was introduced, with complete response. CONCLUSION: Although rare, pleural empyema caused by nontyphoidal Salmonella should be considered in patients with severe immunosuppression, because appropriate antimicrobial therapy with surgical measures are very important for the outcome in these patients.


Subject(s)
Bronchial Neoplasms/immunology , Empyema, Pleural/immunology , Immunocompromised Host , Lymphoma, B-Cell, Marginal Zone/immunology , Neoplasms, Multiple Primary/immunology , Peritoneal Neoplasms/immunology , Pleural Neoplasms/immunology , Salmonella Infections/immunology , Stomach Neoplasms/immunology , Empyema, Pleural/diagnosis , Humans , Male , Middle Aged , Salmonella Infections/diagnosis , Salmonella Infections/microbiology , Salmonella enteritidis/isolation & purification , Tomography, X-Ray Computed
6.
Dis Model Mech ; 8(11): 1413-25, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26398950

ABSTRACT

Staphylococcus aureus necrotizing pneumonia is recognized as a toxin-mediated disease, yet the tissue-destructive events remain elusive, partly as a result of lack of mechanistic studies in human lung tissue. In this study, a three-dimensional (3D) tissue model composed of human lung epithelial cells and fibroblasts was used to delineate the role of specific staphylococcal exotoxins in tissue pathology associated with severe pneumonia. To this end, the models were exposed to the mixture of exotoxins produced by S. aureus strains isolated from patients with varying severity of lung infection, namely necrotizing pneumonia or lung empyema, or to purified toxins. The necrotizing pneumonia strains secreted high levels of α-toxin and Panton-Valentine leukocidin (PVL), and triggered high cytotoxicity, inflammation, necrosis and loss of E-cadherin from the lung epithelium. In contrast, the lung empyema strain produced moderate levels of PVL, but negligible amounts of α-toxin, and triggered limited tissue damage. α-toxin had a direct damaging effect on the epithelium, as verified using toxin-deficient mutants and pure α-toxin. Moreover, PVL contributed to pathology through the lysis of neutrophils. A combination of α-toxin and PVL resulted in the most severe epithelial injury. In addition, toxin-induced release of pro-inflammatory mediators from lung tissue models resulted in enhanced neutrophil migration. Using a collection of 31 strains from patients with staphylococcal pneumonia revealed that strains producing high levels of α-toxin and PVL were cytotoxic and associated with fatal outcome. Also, the strains that produced the highest toxin levels induced significantly greater epithelial disruption. Of importance, toxin-mediated lung epithelium destruction could be inhibited by polyspecific intravenous immunoglobulin containing antibodies against α-toxin and PVL. This study introduces a novel model system for study of staphylococcal pneumonia in a human setting. The results reveal that the combination and levels of α-toxin and PVL correlate with tissue pathology and clinical outcome associated with pneumonia.


Subject(s)
Bacterial Toxins/metabolism , Empyema, Pleural/microbiology , Epithelial Cells/microbiology , Exotoxins/metabolism , Hemolysin Proteins/metabolism , Leukocidins/metabolism , Lung/microbiology , Pneumonia, Staphylococcal/microbiology , Staphylococcus aureus/pathogenicity , Bacterial Toxins/immunology , Cell Line, Tumor , Chemotaxis , Coculture Techniques , Empyema, Pleural/immunology , Empyema, Pleural/metabolism , Empyema, Pleural/pathology , Epithelial Cells/drug effects , Epithelial Cells/immunology , Epithelial Cells/metabolism , Epithelial Cells/pathology , Exotoxins/immunology , Fibroblasts/metabolism , Fibroblasts/microbiology , Fibroblasts/pathology , Hemolysin Proteins/immunology , Humans , Immunoglobulins, Intravenous/pharmacology , Immunologic Factors/pharmacology , Inflammation Mediators/metabolism , Leukocidins/immunology , Lung/drug effects , Lung/immunology , Lung/metabolism , Lung/pathology , Necrosis , Neutrophil Infiltration , Pneumonia, Staphylococcal/drug therapy , Pneumonia, Staphylococcal/immunology , Pneumonia, Staphylococcal/metabolism , Pneumonia, Staphylococcal/pathology , Staphylococcus aureus/classification , Staphylococcus aureus/drug effects , Staphylococcus aureus/immunology , Staphylococcus aureus/metabolism , Time Factors
7.
Rev Med Chir Soc Med Nat Iasi ; 119(1): 38-44, 2015.
Article in English | MEDLINE | ID: mdl-25970940

ABSTRACT

AIM: To detect in patients with psoriasis the adverse effects during TNF-a inhibitor therapy. MATERIAL AND METHODS: Fifty-seven patients with psoriasis, aged between 12 and 75 years were analyzed. They were treated with different TNF-α antagonists, the maximum treatment duration being 59 months. All patients were followed monthly after the initiation of therapy by clinical checkup, then every 3 months during the first 6 months of treatment by laboratory screening, and then every 6 month. Chest x-ray and tuberculin intradermal skin test were performed annually or as needed. All symptoms reported by patients were recorded, the treating doctor deciding the need for additional investigations or specialist consult. RESULTS: Of the total of 57 patients with psoriasis on biological therapy, 9 patients developed diseases requiring temporary or permanent discontinuation of therapy. The recorded adverse reactions were: infectious (pulmonary tuberculosis, pulmonary empyema), oncologic (rectal cancer, renal cancer), dermatologic (vesiculobullous erythema multiforme major, nodular hypodermtis, secondary erythroderma, and hives) disorders. CONCLUSIONS: Despite its adverse reactions, biological therapy is safe and is a necessary tool in the treatment of moderate and severe forms of psoriasis unresponsive to other treatments.


Subject(s)
Biological Therapy/adverse effects , Biological Therapy/methods , Dermatologic Agents/administration & dosage , Dermatologic Agents/adverse effects , Psoriasis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab , Adolescent , Adult , Aged , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/adverse effects , Child , Empyema, Pleural/immunology , Female , Follow-Up Studies , Humans , Infliximab , Kidney Neoplasms/immunology , Male , Middle Aged , Rectal Neoplasms/immunology , Risk Factors , Skin Diseases/immunology , Treatment Outcome , Tuberculosis, Pulmonary/immunology , Tumor Necrosis Factor-alpha/immunology , Young Adult
9.
APMIS ; 122(1): 68-75, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23656439

ABSTRACT

Evidence from a recent randomized study of our group suggests that intravenous clarithromycin resulted in earlier resolution of ventilator-associated pneumonia. The need to understand the mechanism of action of clarithromycin guided to the study of a model of experimental empyema by multidrug-resistant Pseudomonas aeruginosa in 40 rabbits. Animals were randomized into controls (group A); treatment with clarithromycin (group B); treatment with piperacillin/tazobactam (group C); and treatment with both agents (group D). Pleural fluid was collected at regular time intervals for quantitative culture, estimation of cell apoptosis and of concentrations of tumour necrosis factor-alpha (TNFα). After 7 days, animals were euthanized for estimation of tissue growth. Bacterial growth in the pleural fluid of group D was significantly decreased compared with the other groups on day 5. Lung growth of group D was lower than group A. That was also the case of cytokine stimulation by pleural fluid samples on U937 monocytes. It is concluded that administration of clarithromycin enhanced the antimicrobial efficacy of piperacillin/tazobactam and decreased bacterial growth in the pleural fluid and in tissues. It also attenuated the pro-inflammatory phenomena induced by the ß-lactam.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Clarithromycin/therapeutic use , Empyema, Pleural/drug therapy , Empyema, Pleural/microbiology , Pseudomonas Infections/drug therapy , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/therapeutic use , Animals , Anti-Bacterial Agents/administration & dosage , Apoptosis/drug effects , Apoptosis/immunology , Clarithromycin/administration & dosage , Disease Models, Animal , Drug Resistance, Multiple, Bacterial , Drug Therapy, Combination , Empyema, Pleural/immunology , Humans , Interleukin-6/biosynthesis , Male , Penicillanic Acid/administration & dosage , Penicillanic Acid/analogs & derivatives , Piperacillin/administration & dosage , Piperacillin, Tazobactam Drug Combination , Pleural Effusion/immunology , Pleural Effusion/microbiology , Pseudomonas Infections/immunology , Pseudomonas aeruginosa/drug effects , Rabbits , Tumor Necrosis Factor-alpha/biosynthesis , U937 Cells
11.
Diagn Pathol ; 7: 114, 2012 Aug 29.
Article in English | MEDLINE | ID: mdl-22931631

ABSTRACT

Primary lymphoma of adrenal glands is rare, and non-B-cell lymphoma associated with pyothorax is also very rare. Here we report the first autopsy case of non-B-cell lymphoma in bilateral adrenal glands of a 79-year-old woman with pyothorax who had an aggressive clinical course. Immunohistochemically, tumor cells showed CD3+, CD45RO+, CD5-, CD7-, CD4-, CD8-, CD10-, CD20-, CD30-, CD79a-, CD138-, CD56-, granzyme B-, TIA-1+ and ALK-. In addition, tumor cells were strongly EBER1-positive by in situ hybridization. In genomic DNA of tumor cells, T-cell receptor rearrangements were not detected by southern blotting. We finally diagnosed this case as extranodal NK/T-cell lymphoma (nasal type). Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/8050621197741854.


Subject(s)
Adrenal Gland Neoplasms/etiology , Empyema, Pleural/complications , Lymphoma, Extranodal NK-T-Cell/etiology , Adrenal Gland Neoplasms/chemistry , Adrenal Gland Neoplasms/genetics , Adrenal Gland Neoplasms/immunology , Adrenal Gland Neoplasms/pathology , Adrenal Gland Neoplasms/virology , Aged , Autopsy , Biomarkers, Tumor/analysis , Blotting, Southern , Empyema, Pleural/immunology , Empyema, Pleural/pathology , Fatal Outcome , Female , Gene Rearrangement, T-Lymphocyte , Herpesvirus 4, Human/genetics , Humans , Immunohistochemistry , In Situ Hybridization , Lymphoma, Extranodal NK-T-Cell/chemistry , Lymphoma, Extranodal NK-T-Cell/genetics , Lymphoma, Extranodal NK-T-Cell/immunology , Lymphoma, Extranodal NK-T-Cell/pathology , Lymphoma, Extranodal NK-T-Cell/virology , RNA, Viral/genetics , Tomography, X-Ray Computed
12.
Respirology ; 17(1): 114-9, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21848709

ABSTRACT

BACKGROUND AND OBJECTIVE: National surveillance of invasive pneumococcal disease (IPD) includes serotyping Streptococcus pneumoniae (SP) isolates from sterile site cultures. PCR is more sensitive and can identify more SP serotypes (STs) in culture-negative samples. The aim of this study was to determine whether enhanced surveillance of childhood empyema, using PCR, provides additional serotype information compared with conventional surveillance. METHODS: Pleural fluid (PF) from children with empyema were cultured and tested by PCR to identify SP, targeting the autolysin gene (lytA). Multiplex PCR-based reverse line blot assay was used to identify SP STs. Corresponding IPD surveillance and serotype data were obtained from the National Notifiable Diseases Surveillance System (NNDSS). RESULTS: Eighty-nine children with empyema, aged ≤16 years, were recruited between April 2008 and March 2009, inclusive. SP was isolated from 5/84 (5.9%) PF cultures and by PCR in 43/79 (54.4%) PF samples. Serotypes were unidentifiable in 15 samples. The frequency of six serotypes (or serotype pairs) identified in 28 samples, including one with two serotypes, were: ST1, n = 4/29 (13.8%); ST3, n = 9/29 (31.0%); ST19A, n = 12/29 (41.4%); ST7F/7A, n = 1/29 (3.4%); ST9V/9A, n = 1/29 (3.4%); ST22F/22A, n = 2/29 (6.9%). Over the same period, 361 IPD patients, aged 16 years or less, were notified to NNDSS. Among 331 serotypeable NNDSS isolates (71.5% from blood), the frequencies of ST1 and 3 were significantly lower than in PF samples: ST1, n = 8/331 (2.4%; P < 0.05); ST3, n = 13/331 (3.9%; P < 0.0001). CONCLUSIONS: The use of PCR to identify and serotype SP in culture-negative specimens provides additive information.


Subject(s)
Empyema, Pleural/microbiology , N-Acetylmuramoyl-L-alanine Amidase/genetics , Pneumococcal Infections/microbiology , Pneumococcal Vaccines , Polymerase Chain Reaction , Sentinel Surveillance , Streptococcus pneumoniae/genetics , Adolescent , Australia/epidemiology , Child , Child, Preschool , Empyema, Pleural/immunology , Female , Humans , Immunization Programs , Infant , Male , Pneumococcal Infections/epidemiology , Pneumococcal Infections/immunology , Pneumococcal Infections/prevention & control , Predictive Value of Tests , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/immunology , Streptococcus pneumoniae/isolation & purification
14.
Scand J Infect Dis ; 39(1): 80-3, 2007.
Article in English | MEDLINE | ID: mdl-17366020

ABSTRACT

We report a patient with a rare presentation of extra-intestinal salmonellosis after infliximab therapy for rheumatoid arthritis. We discuss the increasing incidence of primary infections and reactivation of intracellular microorganisms after treatment with TNF-alpha blockage, with emphasis on salmonellosis.


Subject(s)
Aneurysm, Infected/microbiology , Anti-Inflammatory Agents/adverse effects , Antibodies, Monoclonal/adverse effects , Empyema, Pleural/microbiology , Salmonella Infections/complications , Salmonella enteritidis/pathogenicity , Sepsis/microbiology , Aged , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/drug therapy , Empyema, Pleural/complications , Empyema, Pleural/immunology , Fatal Outcome , Humans , Infliximab , Male , Salmonella Infections/immunology , Tumor Necrosis Factor-alpha/antagonists & inhibitors
15.
Rheumatol Int ; 27(10): 919-25, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17294192

ABSTRACT

Pleural involvement is the most frequent manifestation of rheumatoid arthritis (RA) in the chest. We report here two patients who presented with large exudative pleural effusions and subsequently developed sero-positive RA. In both cases, the differential cell count of the pleural effusion suggested empyema. A literature review identified that RA-associated pleural effusion afflicts more men than women and 95% of the patients have high titers of rheumatoid factor (RF). In 46% of cases, RA-associated pleural effusion is diagnosed in close temporal relationship with the diagnosis of RA. The effusion is an exudate and is characterized by low pH and glucose level, and high lactic dehydrogenase (LDH) and cell count. At diagnosis there is a tendency for predominant neutrophils to occur consistent with an empyema and 7-11 days later, the cells in the pleural effusion are replaced by lymphocytes. Pleural effusion with predominant eosinophilia is rare. RA patients with acidic effusion and low glucose content with neutrophils predominance should be treated with thoracic drainage and antibiotics until an infection is ruled out. The histo-pathologic findings in pleural fluid of tadpole cells and multinucleated giant cells and the replacement of the mesothelial cells on the parietal pleural surface with a palisade of macrophage derived cells are described as pathogonomic for RA. Treatment with systemic steroids and intra-pleural steroids are effective in most cases.


Subject(s)
Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/diagnosis , Empyema, Pleural/immunology , Pleural Effusion/etiology , Aged , Arthritis, Rheumatoid/drug therapy , Eosinophilia/drug therapy , Eosinophilia/immunology , Humans , Male , Middle Aged , Pleural Effusion/drug therapy , Pleural Effusion/pathology , Steroids/therapeutic use
17.
Semin Arthritis Rheum ; 35(6): 368-78, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16765714

ABSTRACT

OBJECTIVES: To describe the clinical and laboratory features of rheumatoid pleural effusion (RPE) and the diagnostic and therapeutic approaches to this condition. METHODS: The review is based on a MEDLINE (PubMed) search of the English literature from 1964 to 2005, using the keywords "rheumatoid arthritis" (RA), "pulmonary complication", "pleural effusion", and "empyema". RESULTS: Pleural effusion is common in middle-aged men with RA and positive rheumatoid factor (RF). It has features of an exudate and a high RF titer. Underlying lung pathology is common. Generally RPE is small and resolves spontaneously but symptomatic RPE may require thoracocentesis. Rarely, RPE has features of a sterile empyematous exudate with high lipids and lactate dehydrogenase, and very low glucose and pH levels. This type of effusion eventually leads to fibrothorax and lung restriction. Superimposed infective empyema often complicates RPE. Oral, parenteral, and intrapleural corticosteroids, pleurodesis and decortication, have been used for the treatment of sterile RPE. Infected empyema is treated with drainage and antibiotics. CONCLUSIONS: RPE may evolve into a sterile empyematous exudate with the development of fibrothorax. Symptomatic effusions or suspicion of other causes of exudate (infection, malignancy) require thoracocentesis. The "rheumatoid" nature of the pleural exudate in patients without arthritis mandates a pleural biopsy to exclude tuberculosis or malignancy. The optimal therapy of RPE has yet to be established. The role of cytokines in the course of RPE and the possible usefulness of cytokine blockade in the treatment of this RA complication require further evaluation.


Subject(s)
Arthritis, Rheumatoid/complications , Empyema, Pleural/immunology , Pleural Effusion/immunology , Arthritis, Rheumatoid/diagnosis , Collagen Diseases/complications , Empyema, Pleural/etiology , Exudates and Transudates/immunology , Humans , Pleural Effusion/chemistry , Pleural Effusion/diagnosis , Pleural Effusion/therapy
18.
Clin Lab ; 51(9-10): 505-7, 2005.
Article in English | MEDLINE | ID: mdl-16285472

ABSTRACT

We present a case showing the investigation of a 7-year-old girl with empyema and glomerulonephritis whose "immunological" defect was a single complement component (C2) deficiency which prevented her from activating her classical complement pathway. A defect in complement function should be suspected in any patient with severe or recurring pyogenic infections. Investigations of "? immune deficiency" should always include tests to assess the patency of the patient's complement system.


Subject(s)
Complement C2/deficiency , Empyema, Pleural/diagnosis , Glomerulonephritis/diagnosis , Child , Complement C2/analysis , Empyema, Pleural/immunology , Empyema, Pleural/microbiology , Female , Glomerulonephritis/immunology , Humans , Male , Recurrence , Streptococcus pneumoniae/isolation & purification
19.
Khirurgiia (Mosk) ; (2): 4-8, 2005.
Article in Russian | MEDLINE | ID: mdl-15798721

ABSTRACT

Results of treatment of 114 patients with posttraumatic empyema of the pleura (EP) after closed injury of the thorax (62), stab-incised (43) and missile (9) wounds are presented. In complex treatment of 25 patients one of cytokines - recombinant interleukin-1v (betaleukin) -- was administered intravenously (10 patients) and intrapleurally (15 patients). Control group consisted of 35 similar patients treated with traditional methods including drainage and sanitation of empyema's cavity with protheolytic enzymes, antibacterial and detoxication therapy. Comparative analysis has demonstrated that patients of the study group showed fast normalization of immunogram's parameters, decrease of duration of purulent process (51+/-4 days, on the average, in the control group and 28+/-3 days in the study group) due to fast obliteration of purulent cavity, and decrease of rate of chronic forms of EP (from 20 to 4%) which required surgical treatment.


Subject(s)
Drainage/methods , Empyema, Pleural/therapy , Interleukin-1/administration & dosage , Recombinant Proteins/administration & dosage , Thoracic Injuries/complications , Adult , Anti-Bacterial Agents/therapeutic use , B-Lymphocytes/immunology , Empyema, Pleural/etiology , Empyema, Pleural/immunology , Female , Humans , Injections, Intravenous , Lymphocyte Count , Male , Sorption Detoxification , T-Lymphocytes/immunology , Treatment Outcome , Wounds, Gunshot/complications , Wounds, Nonpenetrating/complications , Wounds, Stab/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...